Madeleine Williams
Stock Analyst at Canaccord Genuity
(2.92)
# 2,737
Out of 5,014 analysts
94
Total ratings
47.8%
Success rate
3.5%
Average return
Main Sectors:
Stocks Rated by Madeleine Williams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: CU6 Clarity Pharmaceuticals Ltd | Reiterated: Buy | $8.41 → $8.38 | $2.10 | +299.05% | 13 | Sep 16, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Reiterated: Buy | $24.76 | $20.14 | +22.94% | 8 | Aug 29, 2026 | |
| ASX: CUV Clinuvel Pharmaceuticals Limited | Downgraded: Hold | $27.90 → $9.52 | $8.25 | +15.39% | 3 | Aug 27, 2026 | |
| ASX: MSB Mesoblast Limited | Reiterated: Buy | $3.56 | $2.07 | +71.98% | 7 | Aug 27, 2026 | |
| ASX: MYX Mayne Pharma Group Limited | Reiterated: Buy | $3.83 → $3.75 | $2.85 | +31.58% | 5 | Aug 27, 2026 | |
| ASX: EBR EBR Systems, Inc. | Reiterated: Buy | $2.27 → $1.91 | $0.27 | +620.75% | 12 | Aug 21, 2026 | |
| ASX: ATH Alterity Therapeutics Limited | Reiterated: Buy | $0.95 | $0.41 | +131.71% | 5 | Aug 13, 2026 | |
| ASX: M7T Mach7 Technologies Limited | Reiterated: Hold | $0.27 → $0.32 | $0.23 | +39.13% | 3 | Jul 30, 2026 | |
| ASX: BOT Botanix Pharmaceuticals Limited | Reiterated: Buy | $0.14 | $0.02 | +636.84% | 6 | Jul 29, 2026 | |
| ASX: SNT Syntara Limited | Reiterated: Buy | $0.15 | $0.02 | +614.29% | 9 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.28 | $1.56 | +46.15% | 7 | Jul 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3.15 | $3.40 | -7.35% | 5 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.84 | $2.51 | +13.15% | 3 | Jun 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180.82 → $168.62 | $161.09 | +4.67% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1.27 → $0.40 | $0.03 | +1,112.12% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27.33 → $27.41 | $15.61 | +75.59% | 2 | Oct 15, 2025 |
Clarity Pharmaceuticals Ltd
Sep 16, 2026
Reiterated: Buy
Price Target: $8.41 → $8.38
Current: $2.10
Upside: +299.05%
Neuren Pharmaceuticals Limited
Aug 29, 2026
Reiterated: Buy
Price Target: $24.76
Current: $20.14
Upside: +22.94%
Clinuvel Pharmaceuticals Limited
Aug 27, 2026
Downgraded: Hold
Price Target: $27.90 → $9.52
Current: $8.25
Upside: +15.39%
Mesoblast Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.56
Current: $2.07
Upside: +71.98%
Mayne Pharma Group Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.83 → $3.75
Current: $2.85
Upside: +31.58%
EBR Systems, Inc.
Aug 21, 2026
Reiterated: Buy
Price Target: $2.27 → $1.91
Current: $0.27
Upside: +620.75%
Alterity Therapeutics Limited
Aug 13, 2026
Reiterated: Buy
Price Target: $0.95
Current: $0.41
Upside: +131.71%
Mach7 Technologies Limited
Jul 30, 2026
Reiterated: Hold
Price Target: $0.27 → $0.32
Current: $0.23
Upside: +39.13%
Botanix Pharmaceuticals Limited
Jul 29, 2026
Reiterated: Buy
Price Target: $0.14
Current: $0.02
Upside: +636.84%
Syntara Limited
Jul 8, 2026
Reiterated: Buy
Price Target: $0.15
Current: $0.02
Upside: +614.29%
Jul 4, 2026
Reiterated: Buy
Price Target: $2.28
Current: $1.56
Upside: +46.15%
Jun 11, 2026
Reiterated: Buy
Price Target: $3.15
Current: $3.40
Upside: -7.35%
Jun 6, 2026
Reiterated: Buy
Price Target: $2.84
Current: $2.51
Upside: +13.15%
May 12, 2026
Reiterated: Buy
Price Target: $180.82 → $168.62
Current: $161.09
Upside: +4.67%
Mar 13, 2026
Reiterated: Buy
Price Target: $1.27 → $0.40
Current: $0.03
Upside: +1,112.12%
Oct 15, 2025
Reiterated: Buy
Price Target: $27.33 → $27.41
Current: $15.61
Upside: +75.59%